News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Bitcoin fell to $61,524, down over 16% this week after about $1.4 billion in spot ETF outflows.
  • European and UK stocks fell amid Middle East frictions lifting Brent toward $95 and soft UK housing data.
  • Barclays warned the AI-led semiconductor rally looks overstretched amid heavy positioning, large IPOs and a packed June macro calendar.
  • SpaceX's website and IPO materials were inaccessible from mainland China and Hong Kong during its U.S. roadshow.
  • The U.S. criticised 'two-tiered policing' in the UK over a high-profile murder case, intensifying political divisions and protests.
  • Citi picked Tencent, Alibaba and Baidu as top Chinese AI plays, flagging potential entry points after sector weakness.

Latest Articles

Xos announces $6 million common stock registered direct offering

Xos announces $6 million common stock registered direct offering

Xos, Inc., a US-based leader in electric commercial vehicles and energy storage systems, has announced a registered direct offering of approximately 1.1 million shares of common stock at $5.50 per share, intending to raise about $6 million in gross proceeds. The company plans to use the funds to expand its Power Hub and energy storage business targ…

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Emergent BioSolutions Inc. supports National Naloxone Awareness Day through partnership with Victoria's Voice Foundation to promote opioid overdose education and expand access to NARCAN® Nasal Spray and KLOXXADO® Nasal Spray. The company highlights new initiatives including the NARCAN® Nasal Spray Carrying Case and upcoming outreach in colleges to …

Weight Watchers to Increase Access to Comprehensive Weight Loss Options for Patients Nationwide through LillyDirect

Weight Watchers to Increase Access to Comprehensive Weight Loss Options for Patients Nationwide through LillyDirect

WW International, Inc. announces integration of its Weight Watchers Med+ program with Eli Lilly's digital healthcare platform, LillyDirect, to enhance nationwide patient access to GLP-1 prescription weight loss medications combined with behavioral and clinical support. This collaboration aims to provide a comprehensive and accessible approach to we…

Aya Gold & Silver Releases its 2025 Sustainability Report

Aya Gold & Silver Releases its 2025 Sustainability Report

Aya Gold & Silver Inc. released its 2025 Sustainability Report showcasing meaningful advancements in environmental management—such as reduced water and greenhouse gas intensities—robust social investments in local communities and employee training, and enhanced governance practices including ESG-linked executive incentives and increased female work…

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Inc. and Fountain Life announce the availability of cenplacel-L, a placental-derived allogeneic cell therapy, for investigational use by licensed physicians in Florida under recently enacted state legislation. This new regulatory framework allows use of certain cell therapies without FDA approval, enabling physician-directed application …

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

ARS Pharmaceuticals has announced a collaboration with former NFL star Drew Brees to raise awareness about severe food allergies and the importance of preparedness using neffy®, an FDA-approved needle-free epinephrine nasal spray. This partnership aims to educate patients and caregivers on prompt treatment of severe allergic reactions to prevent an…

ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy

ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy

ChronoScale Corporation announced the appointments of Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to accelerate the company's AI infrastructure platform growth and global compute solutions delivery. These leadership additions aim to strengthen innovation and scale operations to meet rising enterprise demand…

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

NextCure, Inc. announced the availability of a replay for its virtual Key Opinion Leader event discussing the first clinical efficacy data from the Phase 1 dose escalation study of SIM0505, an investigational antibody-drug conjugate targeting Cadherin-6, for ovarian and uterine serous carcinoma cancers. The event featured experts from leading cance…

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Amneal Pharmaceuticals announced FDA approval of its romidepsin injection solution, a ready-to-use formulation that simplifies hospital and pharmacy preparation compared to the previously marketed lyophilized powder. The product’s Competitive Generic Therapy designation grants Amneal 180 days of market exclusivity, enhancing its differentiated inje…

IMUNON Announces Up to $10 Million Cash Financing

IMUNON Announces Up to $10 Million Cash Financing

IMUNON, Inc. announced a structured financing deal raising up to $10 million to fund enrollment in its pivotal Phase 3 OVATION 3 trial of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The financing combines preferred stock issuance and secured promissory notes with favorable terms intended to minimize dilution. Recent Phase 2 …

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Arvinas, Inc. announced its participation in the Michael J. Fox Foundation-supported LRRK2 Investigative Therapeutics Exchange (LITE) and Parkinson’s Precision Medicine Initiative (PPMI) programs. This collaboration aims to advance ARV-102, an investigational PROTAC drug targeting LRRK2 for treating Parkinson’s disease and related neurodegenerative…

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Immutep Limited announced positive interim Phase I clinical trial results for IMP761, a first-in-class LAG-3 agonist antibody targeting autoimmune diseases. The single ascending dose study demonstrated favorable safety, tolerability, and significant pharmacodynamic activity at 7 mg/kg in healthy volunteers. These findings support further clinical d…

BIO-key’s RedChip Future Tech Investor Conference Presentation to be Webcast Wed. June 10 at 3pm ET

BIO-key’s RedChip Future Tech Investor Conference Presentation to be Webcast Wed. June 10 at 3pm ET

BIO-key International's Chairman and CEO will present at the RedChip Future Tech Investor Conference, highlighting the company's significant revenue growth and anticipated profitability in the first half of 2026. The company, a leader in biometric authentication and identity access management, expects 1H 2026 revenues to increase by 50% compared to…

HSBC Sticks with Risk-On Stance, Outlines What Could Force a Change

HSBC Sticks with Risk-On Stance, Outlines What Could Force a Change

HSBC is maintaining an aggressive allocation to risk assets but has been answering repeated client questions on what might trigger a shift to a bearish stance. Chief Multi-Asset Strategist Max Kettner says common concerns such as near-term U.S. earnings, geopolitics and front-end interest-rate moves rank low, while two higher-priority risks - broad…

Loonie Seen Firming If Trade Talks Progress and Domestic Recovery Takes Hold

Loonie Seen Firming If Trade Talks Progress and Domestic Recovery Takes Hold

A poll of foreign exchange analysts conducted May 29 to June 3 shows the Canadian dollar is expected to strengthen modestly against the U.S. dollar over the next year if Canada's economy stabilizes and there is headway in the review of the continental trade pact. Short-term gains hinge on resolution of trade uncertainties and an improvement in dome…

TFS Financial CFO's Transactions Signal Activity Amid Company Milestones

TFS Financial CFO's Transactions Signal Activity Amid Company Milestones

Meredith S. Weil, Chief Financial Officer and Director at TFS Financial CORP (NASDAQ:TFSL), engaged in significant transactions involving the company's common stock on June 2, 2026. These filings detail both sales of existing shares and substantial acquisitions via option exercises. The movements occurred against a backdrop of current market valuat…